Login
$SER
$1.42 +$0.00 (0.0%) After hours

Company Executives

Officer Age In this role Joined 2025 pay Source
Steve Ledger Also a director
Chief Executive Officer and Class II Director
66 Not stated Not stated $637,500
Gregory S. Curhan
Chief Financial Officer
64 Since 2024
2 years
Not stated Not reported
Randall Moreadith, M.D., Ph.D.
Chief Scientific Officer
Title from the Form 4 dated May 21, 2026
72 Not stated 2010 $563,200
Srini Tenjarla, Ph.D.
SVP, CMC & Formulation
Title from the Form 4 dated May 21, 2026
63 Not stated Not stated $527,400

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

From the proxy statement filed Apr 27, 2026 · updated by the 8-K of Jul 22, 2026

Directors
8
serving now
Average tenure
2.7 years
from year joined
CEO also chairs the board
No
Gregory H. Bailey, M.D. and Balkrishan “Simba” Gill
Director Age On board Committees Other public boards 2025 pay Source
Gregory H. Bailey, M.D.
70 2018
8 years
Compensation
BioHaven Ltd., Manx Financial Group, plc, SalvaRx Group, plc $82,616
Balkrishan “Simba” Gill
62 2024
2 years
None stated Foghorn Therapeutics Not stated
Steve Ledger
66 2022
4 years
None stated None stated Paid as CEO
Richard Marshall, CBE, M.D., Ph.D.
59 2024
2 years
Nominating and Corporate Governance
None stated $82,616
Jay Venkatesan, M.D.
54 2025
1 year
Audit Nominating and Corporate Governance · Chair
Elicio Therapeutics, Inc. $222,160
Stephen Brannan, M.D.
69 2025
1 year
Audit Compensation
None stated $255,375
Karen J. Wilson
63 2025
1 year
Audit · Chair Compensation · Chair Nominating and Corporate Governance
Connect Biopharma Holdings Limited, Elicio Therapeutics, Inc. $240,105
Farrell Simon Joined Jul 22, 2026
- -
Audit Committee Compensation Committee
- -

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.

4 disclosed in the proxy filed Apr 27, 2026
Gregory H. Bailey, M.D.
a member of the Company’s Board of Directors
Purchase price of $2.25 per share
March 2026

Led the March 2026 private placement of common stock and pre-funded warrants at $2.25 per share, with accompanying redeemable warrants.

With the Company Open in proxy
Gregory H. Bailey, M.D.
a member of the Company’s Board of Directors
Up to $20 million
September 9, 2025

Unsecured convertible note under which Dr. Bailey agreed to make available borrowings to the Company.

With the Company Open in proxy
Gregory H. Bailey, M.D.
investor in the Series A Convertible Preferred Stock private placement
Approximately $5 million
April 8, 2025

Purchased shares of Series A Convertible Preferred Stock in a private placement at $5.18 per share.

With the Company Open in proxy
Dr. Venkatesan
investor in the Series A Convertible Preferred Stock private placement
Amount not stated
April 8, 2025

Participated as an investor in the April 2025 private placement of Series A Convertible Preferred Stock.

With the Company Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support